Health News Archive - May 09, 2011
MARLBOROUGH, Mass., May 9, 2011 /PRNewswire/ -- CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the transcatheter treatment of Atrial Fibrillation (AF), announced its technology enables a Pulmonary Vein (PV) acute isolation rate of nearly 99%, with approximately 86% of PVs remaining persistently isolated after three months.
WILMINGTON, Del., May 9, 2011 /PRNewswire/ -- Medical device R&D labs and manufacturers now have a personal resource for answers to the often confusing maze of FDA regulations outlined in the Agency's Quality System Regulations (21 CFR 820).
ALBUQUERQUE, N.M., May 9, 2011 /PRNewswire/ -- Lovelace Health System, Inc. has signed a definitive agreement to purchase the assets and operations of the Heart Hospital of New Mexico from MedCath Corporation for $119 million. The 55-bed Heart Hospital in downtown Albuquerque, N.M.
Better infrastructure and targeted programs needed to encourage active travel, finds Rutgers professor and study leader John Pucher.
COLUMBIA, S.C., May 9, 2011 /PRNewswire/ -- You may see your insurance benefits as necessary, important and valuable -- but do you see them as fun? You could starting today with the launch of Youville(SM), a feature of Colonial Life's new web-based Benefits Learning Center. This interactive online tool offers an entertaining way for workers to individualize their benefits education and explore their unique benefits needs.
BEIJING, May 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that Mr. Jacob Ho, Chief Financial Officer, and Ms.
BOSTON, May 9, 2011 /PRNewswire/ -- The Young Faces of ALS Campaign (YFALS) announced today that Yelp has become a sponsor of the "National Cornhole Challenge Day" a day-long tournament being held in South Boston.
BOSTON, May 9, 2011 /PRNewswire/ -- Rhythm announced today results demonstrating that RM-131, the company's novel ghrelin agonist, was highly effective in restoring normal gastric function in animal models of delayed gastric emptying owing to a direct prokinetic effect.
SAN DIEGO, May 9, 2011 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc.
MISSISSAUGA, Ontario, May 9, 2011 /PRNewswire/ -- 2011 First Quarter Total Revenue $565 million, including $36 million related to out-license of ClodermPro forma organic growth for the combined company, excluding the impact of foreign exchange and acquisitions, was approximately 7%Excluding impact from Diastat and Efudex, pro forma organic growth for the combined company was approximately 11%2011 First Quarter GAAP EPS $0.02; Cash EPS $0.62Excluding impact from Cloderm out-licensing, Cash EPS was $0.562011 First Quarter GAAP Cash Flow from Operations was $86 million; Adjusted Cash Flow from Operations was $204 million 2011 Guidance increased to $2.65 - $2.90 Cash EPSValeant Pharmaceuticals International, Inc.